This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Benkert O, Hippius H (2005) Kompendium der Psychiatrischen Pharmakotherapie. Springer Medizin, Heidelberg
Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35:50–56
Bork JA, Rogers T, Wedlund PJ, de Leon J (1999) A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60:469–476
Christensson EG (1989) Pharmacological data of the atypical neuroleptic compound melperone (Buronil). Acta Psychiatr Scand (Suppl) 352:7–15
De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15–27
Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P (2001) Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 23:228–231
Ereshefsky L (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57(suppl 11):12–25
Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Hartter S (2003) Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry 36:3–6
Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, Jonkman JH (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257–268
Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G (2002) Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35:116–118
Kretzschmar R, Otto J, Teschendorf HJ, Worstmann W (1976) Pharmacological investigations of 4′-fluoro-4-(4-methyl-peperidono)-butyrophenone with respect to its sedative and sleep-inducing properties. Arzneimittelforschung 26:1073–1076
Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435–443
Van Beijsterveldt LEC, Geerts RJF, Leysen JE, Megens AAHP, Van den Eynde HMJ, Meuldermans WEG, Heykants JJ (1994) The regional brain distribution of risperidone and its active metabolite 9;hydroxyrisperidone in the rat. Psychopharmacology 114:53–62
Veefkind AH, Haffmans PM, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202–208
Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263–1268
About this article
Cite this article
Köhnke, M.D., Lutz, U., Wiatr, G. et al. Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. Eur J Clin Pharmacol 62, 333–334 (2006). https://doi.org/10.1007/s00228-006-0098-y
- Psychotic Depression